Clinical Trial Update: Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 safety study of SNX-5422 for solid tumor malignancies and lymphoid cancers has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Leukemia
• Lymphoma
• Solid Tumors

Drugs mentioned

• SNX-5422

Snippet

Sponsor: Esanex Inc. | Conditions: Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL) | Phase 1 | Status: COMPLETED